journal article·2026-05Open access

DOTA‐grafted Cationic Polymers Behaving as Powerful Macromolecular Resistance‐reversal Agents (MRRAs) Combating Against New Delhi Metallo‐β‐lactamase (NDM)‐producing Bacteria

Ruixue Wang, Jian Zhang, Yun li, Liping Qiao, Zhuorui Dong, Dandan Cui, Peirong Bai, Liping Li, Bing Cao, Ruiping Zhang

Advanced Science· Volume 13· Issue 27

Abstract

ABSTRACT New Delhi metallo‐β‐lactamase (NDM)‐producing bacteria have posed a significant threat to human health. To navigate this tricky problem, numerous NDM inhibitors have been explored, showing great antibacterial synergy. But there are still be some problems to be tackled, such as suboptimal efficacy, rapid resistance evolution, and high cytotoxicity. Herein, we engineer two macromolecular resistance‐reversal agents (MRRAs) via pharmacophore integration: linear (MRRAL) and nanostructured (MRRAN) topologies, both coordinating metal ion chelator‐DOTA motif into tunable polycationic scaffolds. And we validate their efficacy through 4 clinically isolated NDM‐producing pathogens. MRRAs present excellent effect boosting meropenem (MEM) to fight against those superbugs with the fractional inhibitory concentration indices much less than 0.5. Notably, the nanostructured MRRAN exhibited superior potency compared to its linear counterpart MRRAL under the same concentration of the active group of “DOTA.” Mechanistic studies revealed that MRRAN could achieve bacterial membrane targeting through charge‐mediated accumulation, exerting triple‐action synergistic mechanisms: 1) physical membrane disruption through powerful local cationic surface interactions and hydrophobic force, 2) precise Zn 2 + depletion from membrane‐associated NDM, and 3) localized DOTA enrichment for enhanced metalloenzyme inhibition. Our findings established a paradigm for rational design of macromolecule metalloenzyme inhibitors through spatial organization of pharmacophores, offering a promising therapeutic strategy against NDM‐mediated carbapenem resistance.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Antimicrobial agents and applications · Antibiotic Resistance in Bacteria · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Third Hospital of Shanxi Medical University Shanxi Bethune Hospital Shanxi Academy of Medical Sciences Tongji Shanxi Hospital Taiyuan China

The Radiology Department of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University Taiyuan China

Key Laboratory of Interface Science and Engineering in Advanced Materials Ministry of Education Taiyuan University of Technology Taiyuan China

School of Basic Medical Sciences Shanxi Medical University Taiyuan China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (58)

Show source-provided references
1. W. H. Orgnization https://www.who.int/news‐room/fact‐sheets/detail/antibiotic‐resistance (accessed March 12023).
2. 10.1016/j.lanwpc.2023.10097210.1016/j.lanwpc.2023.100972 ↗
3. 10.1016/S0140‐6736(21)02724‐010.1016/S0140‐6736(21)02724‐0 ↗
4. 10.1128/CMR.00115‐1810.1128/CMR.00115‐18 ↗
5. 10.1186/s12866‐017‐1012‐810.1186/s12866‐017‐1012‐8 ↗
6. 10.1128/aac.00714‐2310.1128/aac.00714‐23 ↗
7. 10.1126/sciadv.add928010.1126/sciadv.add9280 ↗
8. 10.1002/adma.20221076610.1002/adma.202210766 ↗
9. 10.7150/thno.5620510.7150/thno.56205 ↗
10. 10.1080/1040841X.2019.159981310.1080/1040841X.2019.1599813 ↗
11. 10.1038/s41579‐018‐0141‐x10.1038/s41579‐018‐0141‐x ↗
12. 10.1002/med.2166510.1002/med.21665 ↗
13. 10.1128/AAC.00203‐2110.1128/AAC.00203‐21 ↗
14. 10.1016/j.ejmech.2021.11366710.1016/j.ejmech.2021.113667 ↗
15. 10.1007/s10156‐012‐0528‐y10.1007/s10156‐012‐0528‐y ↗
16. 10.1016/j.ejmech.2021.11366710.1016/j.ejmech.2021.113667 ↗
17. 10.1038/nature1344510.1038/nature13445 ↗
18. 10.1016/j.jmb.2019.04.00210.1016/j.jmb.2019.04.002 ↗
19. 10.1038/s41586‐018‐0344‐310.1038/s41586‐018‐0344‐3 ↗
20. 10.1021/acs.molpharmaceut.2c0082110.1021/acs.molpharmaceut.2c00821 ↗
21. 10.1039/D3MD00036B10.1039/D3MD00036B ↗
22. 10.1039/D2CS00558A10.1039/D2CS00558A ↗
23. 10.1016/j.addr.2022.11446310.1016/j.addr.2022.114463 ↗
24. 10.1016/j.progpolymsci.2017.07.00710.1016/j.progpolymsci.2017.07.007 ↗
25. 10.1021/acsinfecdis.0c0063510.1021/acsinfecdis.0c00635 ↗
26. 10.1093/jac/dks37910.1093/jac/dks379 ↗
27. 10.1016/j.jconrel.2017.06.01310.1016/j.jconrel.2017.06.013 ↗
28. 10.1016/j.jconrel.2022.04.03110.1016/j.jconrel.2022.04.031 ↗
29. 10.1016/j.nantod.2012.04.00310.1016/j.nantod.2012.04.003 ↗
30. 10.1016/j.mtbio.2024.10109110.1016/j.mtbio.2024.101091 ↗
31. 10.1021/bm200780r10.1021/bm200780r ↗
32. 10.1002/adfm.20242562510.1002/adfm.202425625 ↗
33. 10.1038/s41467‐023‐40828‐310.1038/s41467‐023‐40828‐3 ↗
34. 10.1016/j.nantod.2021.10118510.1016/j.nantod.2021.101185 ↗
35. 10.1038/s41467‐019‐11503‐310.1038/s41467‐019‐11503‐3 ↗
36. 10.1002/adma.20220665910.1002/adma.202206659 ↗
37. 10.1002/adma.20230768010.1002/adma.202307680 ↗
38. 10.1128/AAC.00203‐2110.1128/AAC.00203‐21 ↗
39. 10.1093/cid/cix89310.1093/cid/cix893 ↗
40. 10.1021/ja045664d10.1021/ja045664d ↗
41. 10.1021/bm300342u10.1021/bm300342u ↗
42. 10.1002/adma.20220406510.1002/adma.202204065 ↗
43. 10.1128/AAC.26.4.54610.1128/AAC.26.4.546 ↗
44. 10.1007/978‐1‐0716‐1843‐1_2110.1007/978‐1‐0716‐1843‐1_21 ↗
45. 10.3390/pathogens1206085310.3390/pathogens12060853 ↗
46. 10.1002/adhm.20230353710.1002/adhm.202303537 ↗
47. 10.1016/j.ejmech.2024.11671410.1016/j.ejmech.2024.116714 ↗
48. 10.1016/j.plabm.2024.e0043610.1016/j.plabm.2024.e00436 ↗
49. 10.1016/j.cca.2009.07.01110.1016/j.cca.2009.07.011 ↗
50. 10.1002/adhm.20230176410.1002/adhm.202301764 ↗
51. 10.1002/advs.20230890510.1002/advs.202308905 ↗
52. 10.1128/AAC.02231‐1510.1128/AAC.02231‐15 ↗
53. 10.3390/antibiotics1109121510.3390/antibiotics11091215 ↗
54. 10.1007/s12325‐020‐01235‐y10.1007/s12325‐020‐01235‐y ↗
55. 10.1007/s00018‐022‐04316‐z10.1007/s00018‐022‐04316‐z ↗
56. 10.5101/nbe.v14i3.p225‐23510.5101/nbe.v14i3.p225‐235 ↗
57. 10.26599/NBE.2024.929006710.26599/NBE.2024.9290067 ↗
58. 10.1021/acsnano.3c1149610.1021/acsnano.3c11496 ↗